PURPOSE: The aim of this project was to develop clinical practice guidelines on the use of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and management of oral mucositis (OM) in cancer patients. METHODS: A systematic review of the available literature was conducted. The body of evidence for the use of each agent, in each setting, was assigned a level of evidence. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. RESULTS: A recommendation was developed in favor of patient-controlled analgesia with morphine in hematopoietic stem cell transplant (HSCT) patients. Suggestions were developed in favor of transdermal fentanyl in standard dose chemotherapy and HSCT patients and morphine mouth rinse and doxepin rinse in head and neck radiation therapy (H&N RT) patients. Recommendations were developed against the use of topical antimicrobial agents for the prevention of mucositis. These included recommendations against the use of iseganan for mucositis prevention in HSCT and H&N RT and against the use of antimicrobial lozenges (polymyxin-tobramycin-amphotericin B lozenges/paste and bacitracin-clotrimazole-gentamicin lozenges) for mucositis prevention in H&N RT. Recommendations were developed against the use of the mucosal coating agent sucralfate for the prevention or treatment of chemotherapy-induced or radiation-induced OM. No guidelines were possible for any other agent due to insufficient and/or conflicting evidence. CONCLUSION: Additional well-designed research is needed on prevention and management approaches for OM.
PURPOSE: The aim of this project was to develop clinical practice guidelines on the use of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and management of oral mucositis (OM) in cancerpatients. METHODS: A systematic review of the available literature was conducted. The body of evidence for the use of each agent, in each setting, was assigned a level of evidence. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. RESULTS: A recommendation was developed in favor of patient-controlled analgesia with morphine in hematopoietic stem cell transplant (HSCT) patients. Suggestions were developed in favor of transdermal fentanyl in standard dose chemotherapy and HSCT patients and morphine mouth rinse and doxepin rinse in head and neck radiation therapy (H&N RT) patients. Recommendations were developed against the use of topical antimicrobial agents for the prevention of mucositis. These included recommendations against the use of iseganan for mucositis prevention in HSCT and H&N RT and against the use of antimicrobial lozenges (polymyxin-tobramycin-amphotericin B lozenges/paste and bacitracin-clotrimazole-gentamicin lozenges) for mucositis prevention in H&N RT. Recommendations were developed against the use of the mucosal coating agent sucralfate for the prevention or treatment of chemotherapy-induced or radiation-induced OM. No guidelines were possible for any other agent due to insufficient and/or conflicting evidence. CONCLUSION: Additional well-designed research is needed on prevention and management approaches for OM.
Authors: Voichita Bar Ad; Gregory Weinstein; Pinaki R Dutta; Arie Dosoretz; Ara Chalian; Stefan Both; Harry Quon Journal: Cancer Date: 2010-09-01 Impact factor: 6.860
Authors: Y Lievens; K Haustermans; D Van den Weyngaert; W Van den Bogaert; P Scalliet; L Hutsebaut; J Fowler; P Lambin Journal: Radiother Oncol Date: 1998-05 Impact factor: 6.280
Authors: S El-Sayed; A Nabid; W Shelley; J Hay; J Balogh; M Gelinas; R MacKenzie; N Read; E Berthelet; H Lau; J Epstein; P Delvecchio; P K Ganguly; F Wong; P Burns; D Tu; J Pater Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: R P Symonds; P McIlroy; J Khorrami; J Paul; E Pyper; S R Alcock; I McCallum; A B Speekenbrink; A McMurray; E Lindemann; M Thomas Journal: Br J Cancer Date: 1996-07 Impact factor: 7.640
Authors: Bernardo Leon Rapoport; Ronwyn van Eeden; Vincent Sibaud; Joel B Epstein; Jean Klastersky; Matti Aapro; Devan Moodley Journal: Support Care Cancer Date: 2017-07-13 Impact factor: 3.603
Authors: Deborah P Saunders; Tanya Rouleau; Karis Cheng; Noam Yarom; Abhishek Kandwal; Jamie Joy; Kivanc Bektas Kayhan; Marianne van de Wetering; Norman Brito-Dellan; Tomoko Kataoka; Karen Chiang; Vinisha Ranna; Anusha Vaddi; Joel Epstein; Rajesh V Lalla; Paolo Bossi; Sharon Elad Journal: Support Care Cancer Date: 2020-02-12 Impact factor: 3.603
Authors: Adepitan A Owosho; SaeHee K Yom; Zhiqiang Han; Kevin Sine; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2016-07-19
Authors: C Orvain; M P Moles-Moreau; S François; M Mercier; F Moal; J F Hamel; E Parot-Schinkel; N Ifrah; M Hunault-Berger; A Tanguy-Schmidt Journal: Support Care Cancer Date: 2014-08-03 Impact factor: 3.603
Authors: Wanessa Miranda-Silva; Wagner Gomes-Silva; Yehuda Zadik; Noam Yarom; Abdul Rahman Al-Azri; Catherine H L Hong; Anura Ariyawardana; Deborah P Saunders; M Elvira Correa; Praveen R Arany; Joanne Bowen; Karis Kin Fong Cheng; Wim J E Tissing; Paolo Bossi; Sharon Elad Journal: Support Care Cancer Date: 2020-11-06 Impact factor: 3.603
Authors: Eline Vanlancker; Barbara Vanhoecke; Tom Sieprath; Janie Bourgeois; Annelore Beterams; Barbara De Moerloose; Winnok H De Vos; Tom Van de Wiele Journal: Exp Biol Med (Maywood) Date: 2018-01-16